EQ vs. MNOV, XFOR, IMUX, EDIT, ABOS, ORMP, ME, ACOG, VOR, and CLLS
Should you be buying Equillium stock or one of its competitors? The main competitors of Equillium include MediciNova (MNOV), X4 Pharmaceuticals (XFOR), Immunic (IMUX), Editas Medicine (EDIT), Acumen Pharmaceuticals (ABOS), Oramed Pharmaceuticals (ORMP), 23andMe (ME), Alpha Cognition (ACOG), Vor Biopharma (VOR), and Cellectis (CLLS). These companies are all part of the "pharmaceutical products" industry.
Equillium vs.
Equillium (NASDAQ:EQ) and MediciNova (NASDAQ:MNOV) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, community ranking, valuation, risk, earnings, profitability, media sentiment and institutional ownership.
In the previous week, MediciNova had 1 more articles in the media than Equillium. MarketBeat recorded 2 mentions for MediciNova and 1 mentions for Equillium. MediciNova's average media sentiment score of 0.00 beat Equillium's score of -0.50 indicating that MediciNova is being referred to more favorably in the news media.
Equillium has a beta of 1.78, indicating that its stock price is 78% more volatile than the S&P 500. Comparatively, MediciNova has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500.
Equillium presently has a consensus target price of $5.00, indicating a potential upside of 676.52%. MediciNova has a consensus target price of $9.00, indicating a potential upside of 391.80%. Given Equillium's higher possible upside, equities research analysts clearly believe Equillium is more favorable than MediciNova.
MediciNova received 174 more outperform votes than Equillium when rated by MarketBeat users. However, 83.72% of users gave Equillium an outperform vote while only 48.39% of users gave MediciNova an outperform vote.
MediciNova has lower revenue, but higher earnings than Equillium. MediciNova is trading at a lower price-to-earnings ratio than Equillium, indicating that it is currently the more affordable of the two stocks.
27.1% of Equillium shares are owned by institutional investors. Comparatively, 9.9% of MediciNova shares are owned by institutional investors. 30.3% of Equillium shares are owned by company insiders. Comparatively, 14.9% of MediciNova shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
MediciNova has a net margin of 0.00% compared to Equillium's net margin of -10.05%. MediciNova's return on equity of -17.55% beat Equillium's return on equity.
Summary
Equillium beats MediciNova on 9 of the 16 factors compared between the two stocks.
Get Equillium News Delivered to You Automatically
Sign up to receive the latest news and ratings for EQ and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Equillium Competitors List
Related Companies and Tools
This page (NASDAQ:EQ) was last updated on 1/20/2025 by MarketBeat.com Staff
Free EQ Stock Alerts